Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy.
about
Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axisChemo-immunotherapy induces tumor regression in a mouse model of spontaneous mammary carcinogenesis.Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study.Immunostimulatory Effects of Melphalan and Usefulness in Adoptive Cell Therapy with Antitumor CD4+ T Cells.Towards curative cancer immunotherapy: overcoming posttherapy tumor escape.Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer.Exploiting dendritic cells in the development of cancer vaccines.ErbB-targeted CAR T-cell immunotherapy of cancer.CAR T-cell immunotherapy: The path from the by-road to the freeway?Therapy-induced microenvironmental changes in cancer.The Janus face of cyclophosphamide: A sterile inflammatory response that potentiates cancer immunotherapy.Role of Interferon Regulatory Factor 1 in Governing Treg Depletion, Th1 Polarization, Inflammasome Activation and Antitumor Efficacy of Cyclophosphamide.Adjuvant IL-7 potentiates adoptive T cell therapy by amplifying and sustaining polyfunctional antitumor CD4+ T cellsImpact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications.The impact of antibiotic usage on the efficacy of chemoimmunotherapy is contingent on the source of tumor-reactive T cells.A bifunctional nanomodulator for boosting CpG-mediated cancer immunotherapy.DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy
P2860
Q33838944-289E6DB9-AFA8-4C86-9B83-E62E5189440EQ37644937-CFBD8C51-37E5-4627-BC90-80A904E3056DQ37675627-FCA7CD7D-2F63-4D1F-94D4-7AF6BC583E76Q37722551-DD6EEBF9-5AC4-435F-B084-756D136F8A15Q38025094-CA289233-5E9C-464F-B24C-2D875AA2868CQ38115968-D8D176E8-18E8-4964-A698-032E7606ECD0Q38148774-D06E9707-00BC-4DCE-B6CE-1AAE6DD59E43Q38389298-32356240-E57C-4FEA-A829-DE96F4CEA638Q38632105-15888EA2-B8B3-417C-9D37-EB3CBAA46FACQ38756772-31C72A54-04FB-43DF-9C93-80FDF21B370EQ41928461-81F22288-0F8F-4B20-A1A5-88D7BBFF2606Q41991396-ECED16B9-C1C0-4E79-9C01-6C2685ADBAF7Q42362935-6A4AF87A-F949-4EE8-A627-41D9905444F2Q47346032-A1D566EC-0613-4D97-A727-932DE5264866Q49276632-2DA81794-6EC2-4E04-B6F4-B4DE08CA71B7Q50072990-7718A3CF-EEC1-4197-B22C-028F2D078973Q56889252-F6CEC1BE-6F01-4331-8F00-B4F76D187698
P2860
Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Exploitation of the propulsive ...... ponse to cancer immunotherapy.
@en
Exploitation of the propulsive ...... ponse to cancer immunotherapy.
@nl
type
label
Exploitation of the propulsive ...... ponse to cancer immunotherapy.
@en
Exploitation of the propulsive ...... ponse to cancer immunotherapy.
@nl
prefLabel
Exploitation of the propulsive ...... ponse to cancer immunotherapy.
@en
Exploitation of the propulsive ...... ponse to cancer immunotherapy.
@nl
P2860
P50
P1433
P1476
Exploitation of the propulsive ...... sponse to cancer immunotherapy
@en
P2093
Imerio Capone
P2860
P356
10.1016/J.MOLONC.2011.11.005
P577
2011-12-03T00:00:00Z